Tirofiban
Cytoprotection
Tianjin Huanhu HospitalSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Cytoprotection cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tenecteplase Tianjin Huanhu Hospital | Phase 2 | B |
Recombinant Human Plasminogen Activator Tianjin Huanhu Hospital | Phase 2 | B |
Same molecule, other indications
Tirofiban is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →